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ABSTRACT 
 Different model systems using osteoblastic cell lines have been developed to 
help understand the process of bone formation. Here we report the establishment of 
two human osteoblastic cell lines obtained from primary cultures upon transduction 
of immortalizing genes. The resulting cell lines had no major differences to their 
parental lines in their gene expression profiles. Similar to primary osteoblastic cells, 
osteocalcin transcription increased following 1,25-Dihydroxyvitamin D3 treatment 
and the immortalized cells formed a mineralized matrix, as detected by Alizarin Red 
staining. Moreover, these human cell lines responded up-regulating ALPL gene 
expression after treatment with the demethylating agent 5-aza- -deoxycytidine 
(AzadC), as shown before for primary osteoblasts. We further demonstrate that 
these cell lines can differentiate in vivo, using a hidroxiapathite/tricalcium phosphate 
composite as a scaffold, to produce bone matrix. More importantly, we show that, 
these cells respond to demethylating treatment, as shown by the increase in SOST 
mRNA levels, the gene encoding sclerostin, upon treatment of the recipient mice 
with AzadC. This also confirms, in vivo, the role of DNA methylation in the 
regulation of SOST expression previously shown in vitro. Altogether our results 
show that these immortalized cell lines constitute a particularly useful model system 
to obtain further insight into bone homeostasis, and particularly into the epigenetic 
mechanisms regulating sclerostin production. 
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INTRODUCTION 
 As it is the case of other primary cells, primary osteoblasts undergo a finite 
number of cell divisions in culture before they enter a state, known as replicative 
senescence [1], where they can no longer divide. Therefore, the use of primary cell 
lines would require a constant re-establishment of fresh cell cultures from explanted 
tissue, a process that can introduce significant variability in research studies[2]. In 
addition, primary human bone cells often show alterations of their phenotypic 
characteristics with increasing passage number. Other model systems, such as 
osteoblastic cell lines of rodent origin [3,4] or human osteosarcoma cell lines [5], 
have been used to try to avoid this problem. However, all those systems have 
specific limitations. The use of cells derived from bone tumors is not advisable, as 
we cannot be entirely aware of the nature of the events that drove the oncogenic 
transformation, or whether these modifications affect their original phenotype. Also, 
the response capacity of these osteosarcoma cell lines to growth hormones and 
other factors might also be altered. Regarding the osteoblastic lines of rodent origin, 
their limitations come from the existence of species-specific characteristics. To 
overcome these problems, researches have developed human primary osteoblasic 
cell lines with extended replicative capacity [6,7]. In order to become useful in 
experimental models, theses cells not only should be able to increase the number 
of cell divisions that can undergo in culture, but they also require the genotypic and 
phenotypic characteristics of the cell line to be preserved throughout the expansion 
process. 
 We have previously shown that the expression of key genes regulating 
human bone homeostasis, such as SOST (encoding sclerostin), ALPL (encoding 
alkaline phosphatase), RANKL (encoding the receptor activator of nuclear factor 
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kappa-B ligand) and OPG (encoding osteoprotegerin), is controlled by changes in 
the methylation status of specific CpG islands located at regulatory regions[8-10]. 
Despite their popularity, in our hands, osteoblastic cell lines of murine origin do not 
reproduce adequately the effect of demethylating agents in human systems, 
highlighting the importance of developing human cell lines that respond to this kind 
of treatments in order to allow us to study their effect in vivo. 
 Here we describe two new osteoblastic cell lines and compare them with 
already available osteoblastic cell lines and primary osteoblasts. The new cell lines 
maintain common markers of primary osteoblastic cells and are able to differentiate 
and mineralize in vitro. More importantly, these two cells lines are capable to 
respond to the demethylating agent AzadC not only in vitro, but also in vivo when 
transplanted into nude mice.  
 
MATERIALS AND METHODS 
 
Isolation of primary osteoblasts and cell cultures 
 Primary human osteoblasts were isolated from femoral heads obtained from 
donors undergoing hip replacement surgery due to osteoarthritis or hip fractures, as 
previously described [10]. In brief, small bone fragments obtained by mechanical 
rupture of the femoral head were washed with PBS to remove bone marrow. After 
the wash, bone fragments were seeded onto a T175 flask and cells were allowed to 
grow for 10 days in standard conditions (5% CO2, 37°C) before the first media 
change. When 80% confluence was reached, cells were trypsinized and used for 
different experiments. 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  
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 The human osteoblastic cell line MG-63 was 
 and 
antibiotics. The human osteoblastic cell line HOS-TE85 was maintained in culture 
with Eagle Minimum Essential Medium (MEM, Sigma-Aldrich, MO, USA) 
supplemented with 10% FBS and antibiotics.  
 For the 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) treatment, this factor was 
added to the culture media at a final concentration of 10-8 M for 48 hours.  
 To induce osteoblastogenesis, cells were switched to osteogenic media 
containing 50 M ascorbic acid, 1 M dexamethasone and 10mM -
glycerophosphate for up to 4 weeks. Media was changed every 2nd day. In order to 
stain calcium deposits, wells were rinsed in phosphate buffered saline (PBS), fixed 
in 70% ethanol for 1 hour and then rinsed with water. For the staining, 40 mM 
Alizarin Red was added to the wells for 15 minutes. Excess solution was rinsed off 
with water and allowed to air-dry [10].  
 For demethylation experiments, all cells were plated at 5000 cells/cm2 and 
treated for 4 days in the presence of 1 or 5 M 5-Aza-2 -Deoxycytidine (AzadC) 
(Sigma Aldrich) prior to the analyses of gene expression. 
 
Immortalization 
 For immortalization, primary cells expanded up to 3 passages were seeded 
on 6-well plates and infected with four different self-inactivating lentiviruses. These 
lentiviruses drive the expression of the following transgenes (i) SV40 large T 
antigen, (ii) c-myc, (iii) E7 and (iv)Id2 (sequences are available on request) from a 
polybrene. After 12h, the culture media containing the lentiviruses was aspirated 
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and fresh cultivation media was added to the cells. Afterwards the cultivation media 
was renewed every two to three days for the next three weeks until colonies of 
proliferating cells became apparent. These proliferative colonies were pooled and 
further expanded.   
Immortalized cell lines are available upon request. 
 
In vivo experiments 
 The in vivo formation of a bone matrix was studied following the 
experimental model proposed by Mankani et al. [11,12]. FoxN1nu athymic nude 
mice were purchased from Harlan Laboratories and housed in a barrier facility 
according to animal care standards established by the European Union. All the 
experiments were reviewed and approved by the Animal Care Committee at the 
University of Cantabria.  
Hidroxyapathyte/Tricalcium phosphate (HA/TCP) composites (Scaffdex) 
used as scaffold were purchased from Sigma. Prior to implantation in the mouse, 
30-40 mgr of the pulverized composite, previously sterilized by autoclaving, were 
incubated with 1.5-2 million cells in 1 ml of serum-free culture media in an 
eppendorf tube. Incubation was performed at 37°C with rotation for 90 minutes. 
After incubation, the tube was centrifuged briefly and excess media was removed. 
The composite-cell mixture was then placed subcutaneously in the back of an 
athymic nude mouse by using a Jamshidi-type needle of 2 mm internal diameter. 
Some mice were treated with AzadC (700 mg/kg per week, divided in 3 doses, 
injected intraperitoneally). 
Once removed from the mice, implants were fixed in 10% formaldehyde for 3 
days at 4°C and decalcified in 20% EDTA in PBS (pH 7.4) for 4 weeks at 4°C with 
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two weekly changes of the EDTA solution. After decalcification, implants were 
embedded in paraffin. Five microns sections were stained with hematoxylin/eosin 
(H&E)[13], Masson-Goldner trichrome[14] or Sirius red[15] following standard 
protocols.  
 
Immunohystochemistry 
 After removing paraffin and rehydration through decreasing concentration 
alcohol solutions and water, antigens were unmasked by exposing the slides to a 
10mM solution of sodium citrate pH 6.0 for 15 minutes. To quench endogenous 
peroxidase activity, sections were treated with 3% hydrogen peroxide in methanol 
for 10 minutes. After extensive washing with PBS for 20 minutes, and exposure to a 
blocking solution (TBST + 5% Goat serum) for 1 hour, the samples were incubated 
overnight with a 1/200 solution of the anti-collagen antibody (Col1a1; ab34710, 
Abcam, Cambridge, UK) in blocking buffer. Samples are then incubated with a 
secondary antibody (Biotinilated affinity purified goat anti-rabbit IgG) diluted in 
blocking solution   for 1 hour, followed by DAB (3, 3'-diaminobenzidine) horseradish 
peroxidase (HRP), and counterstaining with hematoxylin.  
 
Electron microscopy 
 For ultrastructural examination of the extracted implants, samples were 
submerged into 1% paraformaldehyde and 1% glutaraldehyde in 0.1 M phosphate 
buffer, pH 7.4. Subsequently samples were rinsed in 0.1 M phosphate buffer, 
postfixed in 2% osmium tetroxide, dehydrated in acetone and embedded in araldite 
(Durcupan, Fluka, Switzerland). Ultrathin sections stained with uranyl acetate and 
lead citrate were examined with a JEOL 201 electron microscope. 
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Gene expression and SOST methylation analyses.  
 RNA isolation from cell cultures and removed implants and cDNA synthesis 
were performed as previously described[16]. Gene expression levels were 
measured by real time qPCR using Taqman assays (Life technologies) Expression 
levels were calculated relative the TATA Box Binding Protein gene (TBP) or 
GAPDH as 2 ct. as 2 ct .   SOST promoter methylation status was determined by 
quantitative methylation-specific PCR (qMSP), as previously reported[8] 
 
Statistical Analysis 
 
presented as means ± standard error of the mean values. 
 
 
RESULTS  
MORPHOLOGICAL AND TRANSCRIPTIONAL CHARACTERIZATION OF THE 
IMMORTALIZED CELL LINES. 
 
 The primary osteoblastic cultures were isolated from the femoral head of an 
osteoarthritic patient subjected to hip replacement and a patient that suffered an 
osteoporotic hip fracture. The two immortalized cell lines derived from osteoblasts 
obtained from these two patients were named OB50Li and OB52Li, respectively. 
 After isolation and expansion of the primary cells, they were transduced with 
four different lentiviral vectors encoding for (i) SV40 large T antigen (TAg), (ii) c-
myc, (iii) E7 and (iv) inhibitor of DNA binding 2 (Id2), a dominant negative helix-
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loop-helix protein. These genes were identified in a previous screen as factors that 
facilitate the immortalization of primary human osteoblasts (Lipps et al., In 
preparation). For selection of transduced primary cells, we utilized the difference in 
proliferation capacity between the primary human osteoblasts (low proliferation 
capacity) and the infected cells (high proliferation capacity) and maintained the 
infected cells for three weeks with regular media exchange until colonies of 
proliferating cells arose. The individual colonies of immortalized cells were then 
pooled and further expanded. The resulting polyclonal cell lines showed robust 
proliferation and were truly immortalized, as they could be cultivated for more than 
hundred cumulative population doublings showing no signs of senescence.  
 The cell morphology of the OB50Li and OB52Li cell lines under phase-
contrast microscopy was clearly different from that of the original primary cell lines. 
While the primary cells showed the typical spindly shape appearance, the 
immortalized cell lines showed a polygonal shape (Figure 1A). The immortalized 
cell lines typically grew from the initial cell colonies with in a sheet-like pattern until 
confluence was reached.  
 To assay which conditions promote a more sustained growth of these cells 
lines, immortalized cells were seeded in cultures containing different percentages of 
FBS. The proliferation of the two cell lines was enhanced in media with increasing 
concentrations of serum between 1 and 10% (Figure 1B). Both lines proliferated 
stably until they reached confluence, although the OB52Li cell line seemed to be 
slightly less proliferative with a higher doubling time (12.5 hours for OB50Li versus 
14.5 hours for OB52Li). 
 The osteogenic nature of the cell lines can be characterized in vitro by 
assessing the expression of temporally regulated osteogenic markers. Mature 
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osteoblasts produce bone matrix constituents such as osteocalcin (encoded by 
BGLAP) [17]. Osteoblasts also regulate bone matrix mineralization[18] through the 
production of large amounts of alkaline phosphatase, encoded by the ALPL gene 
[19]. Expression analysis of the genes encoding these two proteins revealed that 
the two immortalized cell lines expressed both osteogenic markers, although to a 
different extent (Figure 1C). BGLAP expression levels were similar in the 
immortalized cell lines and in non-transformed primary human osteoblasts (hOBs). 
In fact, the expression levels of the two immortalized cell lines seem to be more 
similar to those of the primary osteoblasts that those of the MG-63 cell line. 
Regarding ALPL, the expression level of this gene in primary osteoblasts was 
considerably higher than that on the osteoblastic cell line MG63, as we have 
previously described [10] (Figure 1C). ALPL expression level in the immortalized 
cell lines was intermediate between primary osteoblasts and MG-63. The 
expression of type 1 collagen (COL1A1) and other genes typical of the osteoblastic 
lineage was lower in the immortalized cell lines than in primary osteoblasts (figure 
1D). 
 
IN VITRO RESPONSE TO THE DEMETHYLATING AGENT 5-AZA- -
DEOXYCITIDINE AND TO VITAMIN D 
  
 In line with previous reports using primary osteoblasts [10], we observed that 
ALPL expression by the OB50Li and OB52Li cell lines increased significantly in 
response to AzadC (p<0.05 versus baseline for all cell types), thus showing that the 
response to this inhibitor of DNA methyltransferases is indeed preserved in the 
OB50Li and OB52Li cell lines (Figure 2A). 
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 The vitamin D active metabolite 1,25(OH)2D3 is one of the main endocrine 
factors regulating bone homeostasis. It can regulate the activity of both bone 
forming cells (osteoblasts) and bone resorbing cells (osteoclasts)[20]. 1,25(OH)2D3 
is known to control osteoblast proliferation, differentiation and mineralization[21] by 
inducing the production of alkaline phosphatase [22-26] and osteocalcin [27,28].  
We cultured the immortalized osteoblastic cell lines in the presence and 
absence of 1,25(OH)2D3 and analysed the expression of BGLAP, the gene 
encoding osteocalcin, which is involved in the mineralization process. (Figure 2B). 
Quantitative real time PCR (qPCR) analysis demonstrated, in both cell lines, an up-
regulation of the osteoblastic marker BGLAP in response to 1,25(OH) 2D3, which is 
consistent with previous results obtained in primary osteoblasts[29].  
 
MINERALIZATION  
 
 In order to check whether these immortalized cell lines were able to produce 
an osteoid-like mineralized matrix, we incubated confluent hOBs and immortalized 
osteoblasts for 28 days in an osteogenic culture medium and determined their 
mineralization potential by Alizarin red staining at different time points  (Figure 2C). 
Figure 2C clearly shows that both immortalized cell lines are able to form a 
mineralized matrix in response to stimuli inducing osteogenic differentiation. ALPL 
is mainly expressed during the initiation of the mineralization process and is soon 
observed on the cell surface, however its expression declines later in the 
developmental program. Consistent with this, we found a decrease in the 
expression levels of ALPL during the mineralization process (Figure 2D), which is 
also consistent with previous reports in primary osteoblasts [10]. 
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 The final stage of osteoblast differentiation is also accompanied by the up-
regulation of genes more characteristic of the osteocyte phenotype, such as SOST, 
encoding sclerostin, or the gene encoding the fibroblast growth factor 23 (FGF23). 
Similar to the results previously obtained with primary osteoblasts, none of these 
transcripts were detectable by qPCR in either the non-transformed or the 
immortalized osteoblasts (data not shown). 
 
ANALYSIS OF THE BONE FORMING ACTIVITY OF THE IMMORTALIZED 
OSTEOBLASTIC CELL LINES IN VIVO. 
 
 In order to assay the bone forming capacity of the OB50Li and OB52Li lines 
in vivo, both cell lines were seeded onto an HA/TCP scaffold prior to subcutaneous 
implantation in FoxN1nu athymic nude mice. As control, we also performed the same 
procedure with human primary osteoblasts (hOBs) and the osteosarcoma cell line 
HOS-TE85. After three months, the implants were surgically removed and the 
extent of new bone formation was analysed by gene expression and histological 
techniques. It is important to note that no tumor formation was observed in the nude 
mice after the three months period demonstrating that the novel cell lines are 
immortalized but not oncogenically transformed. 
 The H&E staining revealed the existence of cell infiltrations between the 
scaffold particles. The scaffold pores contained a large number of cells distributed 
throughout the scaffold and/or bone matrix, irrespective of the cell type initially 
seeded in the scaffold (Figure 3A, H&E column). Immunohistochemistry analysis 
also showed that all implants were immuno-reactive for Collagen type I (Figure 3A, 
IHQ COL1a1 column) with a very low background labelling, although its presence 
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was more noticeable in the case of the primary osteoblasts and the immortalized 
cell lines OB50Li and OB52Li (Figure 3A, IHQ COL1a1 column). This was also 
shown using the Masson-Goldner technique (Figure 3A, Masson column), a widely 
used histological technique that stains collagen in a blue/green colour. Bone-type 
matrix was not very abundant and looked somewhat immature, but immortalized 
cells and primary non-transformed cells laid similar amounts of matrix. Interestingly, 
observation of the implants at higher magnification, revealed some cells embedded 
within the matrix and surrounded by a clear region, resembling the morphology of 
osteocytes within osteocytic lacunae  (Figure 3B).  
 The samples were stained with Sirius Red to observe the disposition of 
collagen fibres under polarized light. In Figure 4A it is possible to observe clear 
bright areas that would correspond to the birefringence of collagen fibres structured 
in an antiparallel disposition, characteristic of the organized lamellar bone. 
Additionally, the auto-fluorescence of bone was also detected in these samples 
when observed under green fluorescent light (Figure 4B).  
 Electron microscopy studies confirmed the presence of collagen fibres laid in 
an antiparallel orientation (Figure 4C1), dense mineralization vesicles (Figure 4C2), 
cells embedded in the collagen matrix (Figure 4C3) and polarized osteoblasts with 
extensive rough endoplasmic reticulum (Figure 4C4). 
 To analyse the in vivo osteogenic signature of the immortalized cells, we 
isolated mRNA from the implants and carried out quantitative PCR analysis for the 
osteogenic markers ALPL, COL1A1 and SOST using oligonucleotides specific for 
the detection of the human genes. ALPL and SOST were expressed in implants of 
both immortalized cell lines, although to a different extent, as shown in Figure 5A. 
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Also, confirming the histological results, the expression of COL1A1 was detected in 
the implants.   
  
IN VIVO RESPONSE TO THE DEMETHYLATING AGENT AZA-DEOXYCITIDINE 
 
 In our hands, osteoblastic cell lines of murine origin do not reproduce 
adequately the effect of demethylating agents in human systems. We tested 
whether the immortalized cell lines were able to respond to treatment with the 
demethylating agent AzadC in vivo. For this purpose, mice harbouring implants 
were treated with AzadC for a month. Control mice were injected with an equivalent 
volume of saline solution (Figure 5B).  As shown in Figure 5C, treatment with 
AzadC significantly increased the expression levels of sclerostin in both 
immortalized cell lines and in the human osteosarcoma cell line HOS-TE85 to a 
similar level.  In line with this, by using qMSP we confirmed that the methylation of 
the promoter of the SOST gene was decerased by AzadC treatment (not shown). 
 
DISCUSSION 
 Osteoporosis is a disorder characterized by a low bone mass. It results from 
the uncoupled activity of bone resorbing osteoclasts and bone-forming osteoblasts. 
Given the high prevalence of osteoporosis among postmenopausal women and old 
men, intense research is on going in order to get a deeper understanding of the 
disease pathogenesis and to discover new drug targets. In fact, although potent 
anti-resorbing drugs are available, the armamentarium to stimulate bone formation 
is much more limited. Hence there is a strong interest in the development of 
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experimental models allowing to effectively screen interventions promoting bone 
formation. 
 Osteoblasts are responsible for the formation of new bone and therefore a 
tight control of their activity is key for skeletal homeostasis. A variety of cell lines 
from mouse and human origins have been described and are frequently used, 
along with primary osteoblasts, as models to study osteoblast activity. However, 
given the rapid loss of replicative potential of the primary human osteoblasts, there 
is a need for alternative models. On the other hand, spontaneously immortalized 
human osteoblastic cell lines may accumulate a number of DNA changes and they 
may not preserve adequately the normal phenotype. In this work, we describe the 
generation and characterization of two new human osteoblastic cell lines that were 
immortalized by the controlled transfection of a set of survival genes. They had a 
number of characteristics resembling those of normal osteoblasts, including the 
expression of genes typical of osteoblasts and the ability to form an osteoid-like 
matrix, both in vitro and in vivo.  
 We showed that these cells appeared to preserve many of the 
characteristics of primary osteoblasts. They are able to proliferate normally and 
express typical osteogenic markers, such as BGLAP and ALPL. Indeed BGLAP 
expression levels in the OB50Li and OB52Li cell lines are closer to the primary cell 
lines that those of MG-63 cells, a popular osteoblastic line. Small differences in the 
osteocalcin transcriptional levels between the two immortalized cell lines could be 
related to difference in age of the donors or in their bone health status as previously 
described [30,31]. We detected a lower level of expression of ALPL in the 
immortalized cell lines compared to primary human osteoblasts, a difference that 
could indicate a more advanced maturation stage. Since the levels of ALPL have 
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been shown to be regulated by the methylation levels of its promoter region, this 
lower expression level of ALPL in the immortalized cell lines probably reflects a 
higher level of methylation of the ALPL promoter in those lines. In line with this 
hypothesis, we have shown that the immortalized cell lines are able to respond, in 
vitro, to the demethylating agent AzadC. In contrast, primary osteoblasts have an 
already hypomethylated ALPL promoter and, consequently, do not increase gene 
expression in response to AzadC [10]. Likewise, the immortalized cell lines are able 
to respond to 1,25(OH)2D3 by up-regulating BGLAP, contrasting with the absence of 
response seen in MG-63 cells, indicating that the regulatory mechanisms driven by 
vitamin D are also preserved in these cell lines. The small differences between the 
two immortalized cell lines might again reflect different stages of maturation [32,33]. 
Moreover, when maintained in an osteogenic culture medium the two immortalized 
cell lines are able to form a mineralized matrix. This is concomitant with the down-
regulation of ALPL, a marker which expression is known to decrease rapidly during 
the mineralization process, as shown in primary osteoblast cultures. However, we 
were not able to detect the expression of osteocyte specific genes, such as SOST 
or FGF23, in cultures of the immortalized cells lines maintained for several weeks in 
vitro. Similarly, those genes were not detected in long-term cultures of primary 
osteoblasts. These results suggest that current in vitro models are not able to 
induce a terminal differentiation of osteoblasts into osteocytes.   
 Notably, the two cell lines are able to produce bone matrix in vivo, when cells 
are seeded in a HA/TCP scaffold and implanted in extra-skeletal tissues of athymic 
nude mice. For bone tissue to develop from cells implanted in vivo, a scaffold is 
needed to provide both a surface and a space for the growth of new cells. 
Hydroxyapatite/tricalcium phosphate (HA/TCP) particles mimic the natural bone 
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matrix in humans and have been shown to provide an appropriate environment for 
the growth of bone tissue [34-36]. The analysis by qPCR confirmed the expression 
of different bone markers in the implants seeded with the immortalized cells lines. 
These results confirm that the HA/TCP scaffolds can support the growth of the 
immortalized cell lines, and that these cell lines can differentiate to produce human 
bone matrix in vivo. 
 Recent findings have shown that DNA methylation of regulatory regions is a 
key mechanism controlling expression of osteogenic genes. Of particular interest is 
the regulation of SOST, the gene encoding sclerostin, an important inhibitor of bone 
formation. However, in our hands, mouse immortalized osteoblastic cell lines do not 
seem to respond in vivo to the demethylating agent AzadC and therefore are not a 
good model to study the regulation of osteoblast differentiation by DNA methylation 
in general, and SOST/sclerostin regulation in particular.  Importantly, we have 
shown that the two immortalized cell lines presented here are able to respond in 
vivo to the treatment with AzadC by up-regulating SOST expression. Sclerostin is a 
critical factor in the regulation of bone formation. In fact, neutralizing anti-sclerostin 
antibodies are being developed as a new therapy for osteoporosis [37,38]. 
However, the mechanisms regulating sclerostin expression are not well established. 
This is largely due to the fact that sclerostin production is limited to osteocytes and 
to the absence of human osteocytic cell lines. The fact that our immortalized cell 
lines respond to AzadC treatment by up-regulating the expression of the SOST 
gene after transplantation into nude mice confirms previous results in vitro and 
makes these cell lines useful models to study the regulatory effects of DNA 
methylation on cells of the osteoblastic lineage in vivo. 
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FIGURE LEGENDS 
 
FIGURE 1. Phenotypic characteristics of the immortalized cell lines. (A) 
Morphology of cells from primary osteoblastic cultures and their immortalized 
counterparts. (B) Growth curve of the OB50Li and OB53Li cell lines growing in 
media supplemented with increasing concentrations of Fetal Bovine Serum. (C) 
Comparison of osteocalcin (BGLAP) and alkaline phosphatase (ALPL) expression 
levels between the human sarcoma cell line MG-63, primary human osteoblasts 
(OBs) and the two immortalized cell lines. (D) Expression levels of other genes in 
OBs and the cell lines. Values reflect averages of triplicate samples. Bars represent 
standard error of the mean. 
 
FIGURE 2. Response to AzadC and vitamin D and mineralization in vitro. (A) 
ALPL expression in OBs and the immortalized cells in response to AzadC (5 M for 
3 days). Bars represent the mean fold change in comparison with baseline 
expression in a representative triplicate experiment.   (B) Quantitative PCR showing 
the relative expression levels of BGLAP in response to Vitamin D treatment. The 
graph represents the average values from 3 independent cultures. Bars represent 
standard error of the mean values. (C) Left panel. Time course of calcification in 
human primary osteoblasts (hOBs) and in the immortalized cell lines. Picture shows 
Alizarin Red staining of the mineralized matrix. Right panel. qPCR of ALPL 
expression during the mineralization process in the immortalized cell lines. The 
graph represents the average values from 3 independent cultures. Bars represent 
standard error of the mean values. 
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FIGURE 3. H&E and Masson-Goldner staining, and Col1a1 
immunohistochemistry indicating bone forming activity of the immortalized 
osteoblastic cell lines in vivo. (A) Pictures show histological analysis of sections 
obtained from decalcified implants. H&E (a, d, g and j) and Masson Goldner 
staining (c, f, i and l) showing mineralized matrix. Immunohistochemistry analysis of 
the correspondent sections using a Col1a1 antibody (b, e, h and k) where arrows 
indicate regions rich in COL1a1. Magnification 8X. (B) Arrows indicate osteocytes-
like cells surrounded by lacunae and immersed in the mineralized matrix. Asterisks 
mark some of the HA/TCP scaffold particles. Magnification 40X. 
 
FIGURE 4. Sirius Red staining and fluorescence and electron microscopy 
analysis of histological sections. (A) Polarization microscopy of Sirius red 
stained collagen fibres, showing birefringence of collagen enriched areas. Scale bar 
5 µm. (B) H & E stained slides observed under green fluorescent show the typical 
auto-fluorescence of collagen fibers. Scale bar 5 µm. (C) Electron microscopy 
analysis of the implants seeded with the OB52Li immortalized cell lines showing 
collagen fibres laid in an antiparallel orientation (1), dense mineralization vesicles 
(2), cells embedded in the collagen matrix (3) and polarized osteoblasts with an 
active reticulum (4). Scale bars: 1, 2µm; 2-4, 5µm. 
 
FIGURE 5. In vivo expression of osteogenic markers  and response to AzadC 
response. (A) Graphs show the in vivo expression of different osteogenic markers 
(SOST, ALPL and COL1A1) in the implants initially seeded with the immortalized 
cell lines (OB50Li and OB52Li), with human primary osteoblasts (Obs) and with the 
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human osteosarcoma cell line HOS-TE85 (HOS). Primers used were specific for the 
amplification of the human transcripts. (B) 2 months after implantation mice 
harbouring the implants were treated with AzadC for four weeks before implant 
removal. Control mice were injected with saline solution. (C) Graphs represent in 
vivo expression levels of sclerostin in the control mice and mice treated with AzadC 
for four weeks. The graph represents the average values from 3 independent 
cultures. Bars represent standard error of the mean values. P<0.05 (*), P< 0.01 (**). 
 
 
 





